Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
Two pediatric patients with Rett syndrome dosed in the United States with NGN-401, Neurogene’s lead gene therapy product candidate leveraging its proprietary EXACT gene regulation technology
NGN-401 has been well-tolerated to date with no treatment-emergent or procedure-related serious adverse events (SAEs) or transgene-related overexpression toxicity
Third patient dosing anticipated in 1Q24, and interim efficacy data from multiple patients in the first cohort remains on track for 4Q24
NGN-401 design and delivery approach optimized to maximize efficacy and safety profile
https://www.neurogene.com/press-rel...female-pediatric-patients-with-rett-syndrome/
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.78 |
Change
0.480(2.49%) |
Mkt cap ! $2.516B | |||
| Open | High | Low | Value | Volume |
| $19.80 | $20.00 | $19.40 | $2.880M | 146.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 275 | $19.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.79 | 588 | 10 |
View Market Depth
| Last trade - 15.56pm 11/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |